Building on Part 1, which examined how the WHI and NHS studies shaped perceptions of MHT risks—particularly regarding breast cancer and cardiovascular disease—this section delves deeper into MHT’s broader health benefits. Modern research highlights how MHT supports cognitive resilience, cardiovascular health, bone strength, and skin integrity. By preserving brain function, vascular health, bone density, and skin elasticity, MHT contributes significantly to overall well-being during and after menopause.

The Role of Estrogen, Progesterone, and Testosterone in Health

Brain Function & Cognitive Health

The Research

• Estrogen, particularly 17β-estradiol (E2), plays a vital role in enhancing neuroplasticity, supporting memory, and cognitive processing. It promotes synaptic density in the hippocampus, a key region for memory formation, and supports essential processes such as synaptic plasticity, glucose metabolism, mitochondrial function, and neurotransmitter regulation. The sudden decline in E2 during menopause disrupts these processes, contributing to cognitive decline and potentially increasing the risk of Alzheimer’s disease (AD).

• Progesterone also offers neuroprotective benefits, helping to reduce anxiety and improve sleep by modulating GABAergic neurotransmission. However, synthetic progestins, such as medroxyprogesterone acetate (MPA), used in some hormone therapies, may counteract estrogen’s neuroprotective effects. In contrast, bioidentical progesterone is considered to have beneficial or neutral effects, depending on the context and application.

• The type of estrogen and progestin used in MHT is critical. Bioidentical transdermal 17β-estradiol (E2) appears to have stronger neuroprotective effects compared to conjugated equine estrogens (CEE). Additionally, transdermal estradiol bypasses liver metabolism, potentially reducing the risks associated with oral estrogen therapy.

• Testosterone supports brain health and cognition by promoting neurotransmitter balance, enhancing focus, motivation, and mood regulation. It aids in synaptic plasticity, supports memory and processing speed, and has neuroprotective and anti-inflammatory effects. Testosterone may also reduce amyloid beta accumulation, lowering the risk of neurodegenerative diseases like Alzheimer’s. Additionally, it enhances mental energy, confidence, and goal-directed behavior, contributing to overall cognitive resilience.

Mixed Evidence

• While some studies suggest that early initiation of MHT may reduce the risk of Alzheimer’s disease, some recent large-scale studies raise concerns that prolonged MHT use may increase dementia risk. However, it remains unclear whether this risk is directly caused by MHT or reflects underlying predispositions in women who use it.
• Importantly, progestin-only treatments, vaginal estrogen, and transdermal 17β-estradiol have not been associated with an increased risk of dementia. Women who used transdermal 17β-estradiol in early menopause exhibited less brain atrophy and better cognitive function compared to non-users or those taking oral estrogens. In contrast, both continuous and cyclic estrogen-progestin regimens have been linked specifically to an increased risk of Alzheimer’s disease and all-cause dementia. Furthermore, brain imaging studies show that estrogen loss correlates with metabolic decline and increased amyloid deposition—key hallmarks of Alzheimer’s disease.

Cardiovascular Health

The Research

• Estrogen promotes vasodilation by increasing nitric oxide production, enhancing endothelial function, and reducing vascular stiffness. It also improves lipid profiles by increasing HDL and reducing LDL cholesterol, contributing to overall cardiovascular health.

• Progesterone exhibits anti-inflammatory properties, potentially reducing plaque formation by modulating immune responses and decreasing the expression of inflammatory cytokines in arterial walls.

• Testosterone supports vascular health by increasing nitric oxide bioavailability, enhancing vasodilation, and improving heart muscle strength. It also influences vascular remodeling and helps maintain healthy cholesterol levels.

The Timing

• The timing hypothesis suggests that starting MHT early (within 10 years of menopause) may provide cardiovascular benefits by preserving vascular integrity, whereas late initiation may have a negligible impact on heart disease risk due to established vascular damage. However, findings vary based on MHT formulation, dosage, and route of administration.

Bone Density & Osteoporosis Prevention

The Research

• Estrogen stimulates bone formation by inhibiting osteoclast activity, preserving bone mineral density.

• Due to its minimal systemic adverse effects, transdermal estrogen is widely used for the prevention of osteoporosis in postmenopausal women. A meta-analysis of nine clinical trials demonstrated that transdermal estrogen significantly increased bone mineral density (BMD). After one and two years of therapy, lumbar spine BMD increased by 3.4% and 3.7%, respectively, compared to baseline. These results suggest that transdermal estrogen effectively enhances BMD and protects bone structure, with minimal heterogeneity observed across studies.

• Progesterone supports calcium metabolism by enhancing osteoblast activity, playing a crucial role in bone remodeling and reducing fracture risk. It helps regulate bone turnover and maintains bone mass, particularly when used alongside estrogen therapy.

• Testosterone contributes to muscle mass preservation, indirectly benefiting bone stability and reducing fall risk in aging women. It also stimulates bone formation by promoting the differentiation of mesenchymal stem cells into osteoblasts, further enhancing bone strength and reducing the risk of osteoporosis.

The Compelling Findings

• MHT has been consistently shown to reduce fracture risk in postmenopausal women, particularly with early intervention. However, benefits diminish after discontinuation.

Skin, Hair, and Connective Tissue Integrity

The Research

• Estrogen maintains collagen production by stimulating fibroblast activity, preventing skin thinning, promoting elasticity, and enhancing hydration, which helps maintain a youthful appearance. Estrogen receptors are present in the dermis and epidermis, and their activation enhances skin thickness and improves wound healing. It also increases hyaluronic acid synthesis, boosting skin moisture levels and reducing transepidermal water loss.

• Testosterone contributes to hair growth and follicle maintenance by influencing androgen receptor activity in dermal papilla cells, which are critical for hair follicle development and cycling. Testosterone deficiency is linked to hair thinning and increased shedding, particularly in androgen-sensitive areas such as the scalp. Adequate testosterone levels help maintain hair density and quality by supporting hair follicle nutrition and health.

• Progesterone supports connective tissue integrity by regulating collagen synthesis, reducing ligament laxity, and enhancing skin resilience. It stabilizes skin matrix components by promoting the balance between collagen production and degradation, thereby reducing skin sagging and supporting joint stability. Progesterone also modulates fibroblast activity, contributing to the maintenance of dermal structure and strength.

The Ongoing Debate

• Mixed Evidence: MHT is commonly used for skin rejuvenation, with estrogen-based therapies showing notable improvements in skin hydration and elasticity. However, the long-term effects on aging skin remain debated. Some synthetic progestins may negatively impact skin health by reducing collagen synthesis and altering skin pH, potentially accelerating skin aging and increasing the risk of dryness and irritation.

Conclusion: Making an Informed Choice

MHT can play a valuable role in enhancing cognitive function, cardiovascular integrity, bone strength, and skin health. Early initiation and personalized approaches may help preserve neurological resilience, support vascular health, protect against osteoporosis, and maintain youthful skin and connective tissue integrity.

Making informed decisions about menopausal hormone therapy (MHT) requires understanding the latest research and consulting with healthcare providers. Key considerations include individual health history, hormone formulations, timing of initiation, and administration routes. Bioidentical hormones, especially transdermal 17β-estradiol and progesterone, are often linked to more favorable health outcomes, while synthetic hormone alternatives may carry additional risks. Personalized MHT strategies can help optimize long-term well-being and minimize potential side effects.

However, MHT alone is rarely sufficient to address the full spectrum of health needs during menopause. Achieving optimal results often requires a comprehensive approach that integrates lifestyle modifications, nutrition, and other supportive therapies. These complementary strategies will be explored in Part 4 of this series.

References

• Abdi, F., Mobedi, H., Bayat, F., Mosaffa, N., Dolatian, M., & Ramezani Tehrani, F. (2017). The Effects of Transdermal Estrogen Delivery on Bone Mineral Density in Postmenopausal Women: A Meta-analysis. Iranian Journal of Pharmaceutical Research, 16(1), 380-389. PMID: 28496491. PMCID: PMC5423263.
• Brincat, M. and Pollacco, J., 2024. Menopause and the effects of hormone replacement therapy on skin aging: A short review. Gynecological and Reproductive Endocrinology & Metabolism, 5, pp.34–37
• Cho, L., Kaunitz, A.M., Faubion, S.S., Hayes, S.N., Lau, E.S., Pristera, N., Scott, N., Shifren, J.L., Shufelt, C.L., Stuenkel, C.A. and Lindley, K.J., 2023. Rethinking menopausal hormone therapy: For whom, what, when, and how long? Circulation, 147(7).
• Collins, B.C., Laakkonen, E.K. and Lowe, D.A., 2019. Aging of the musculoskeletal system: How the loss of estrogen impacts muscle strength. Bone, 123, pp.137–144.
• Davis, S.R., Baber, R., Panay, N., Bitzer, J., Cerdas Perez, S., Islam, R.M., Kaunitz, A.M., Kingsberg, S.A., Lambrinoudaki, I., Liu, J., Parish, S.J., Pinkerton, J., Rymer, J., Simon, J.A., Vignozzi, L. and Wierman, M.E., 2019. Global consensus position statement on the use of testosterone therapy for women. Climacteric, 22(5), pp.429-434.
• Dubey, R.K., Imthurn, B., Zacharia, L.C. and Jackson, E.K., 2004. Hormone replacement therapy and cardiovascular disease: What went wrong and where do we go from here? Hypertension, 44(6).
• Hodis, H.N. and Mack, W.J., 2022. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: It’s about time and timing. Cancer Journal, 28(3), pp.208–223.
• Jett, S., Schelbaum, E., Jang, G., Boneu Yepez, C., Dyke, J.P., Pahlajani, S., Brinton, R.D. & Mosconi, L. 2022, ‘Ovarian steroid hormones: A long overlooked but critical contributor to brain aging and Alzheimer’s disease’, Frontiers in Aging Neuroscience, vol. 14
• Kalenga, C.Z., Metcalfe, A., Robert, M., Nerenberg, K.A., MacRae, J.M. and Ahmed, S.B., 2023. Association between the route of administration and formulation of estrogen therapy and hypertension risk in postmenopausal women: A prospective population-based study. Hypertension, 80(7).
• Kim, Y.J., Soto, M., Branigan, G.L., Rodgers, K. & Brinton, R.D. 2021, ‘Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy’, Alzheimer’s & Dementia: Translational Research & Clinical Interventions, vol. 7, no. 1, e12174.
• Lephart, E.D. and Naftolin, F., 2022. Factors influencing skin aging and the important role of estrogens and selective estrogen receptor modulators (SERMs). Clinical, Cosmetic and Investigational Dermatology, 15, pp.1695–1709.
• Lorentzon, M., Johansson, H., Harvey, N.C., Liu, E., Vandenput, L., Crandall, C.J., Cauley, J.A., LeBoff, M.S., McCloskey, E.V. and Kanis, J.A., 2022. Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability—results from the Women’s Health Initiative hormone therapy trials. Osteoporosis International, 33(11), pp.2297–2305.
• Maki, P.M., & Henderson, V.W. (2021). ‘Alzheimer’s Disease Prevention: The Role of Menopausal Hormone Therapy’. Current Alzheimer Research, 18(3), 221-232.
• Mills, Z.B., Faull, R.L.M. and Kwakowsky, A., 2023. Is hormone replacement therapy a risk factor or a therapeutic option for Alzheimer’s disease? International Journal of Molecular Sciences, 24(4), p.3205.
• Pourhadi, N., Mørch, L.S., Holm, E.A., Torp-Pedersen, C. & Meaidi, A. 2023, ‘Menopausal hormone therapy and dementia: nationwide, nested case-control study’, BMJ, vol. 381, e072770.
• SenthilKumar, G., Katunaric, B., Bordas-Murphy, H., Sarvaideo, J. and Freed, J.K., 2023. Estrogen and the vascular endothelium: The unanswered questions. Endocrinology, 164(6), p.bqad079.
• Shufelt, C.L. and Manson, J.E., 2021. Menopausal hormone therapy and cardiovascular disease: The role of formulation, dose, and route of delivery. Journal of Clinical Endocrinology & Metabolism, 106(5), pp.1245–1254
• Tomczyk, K., Chmaj-Wierzchowska, K., Wszołek, K. and Wilczak, M., 2023. New possibilities for hormonal vaginal treatment in menopausal women. Journal of Clinical Medicine, 12(14), p.4740.
• Zhang, G.Q., Chen, J.L., Luo, Y., Mathur, M.B., Anagnostis, P., Nurmatov, U., Talibov, M., Zhang, J., Hawrylowicz, C.M., Lumsden, M.A., Critchley, H., Sheikh, A., Lundbäck, B., Lässer, C., Kankaanranta, H., Lee, S.H. and Nwaru, B.I., 2021. Menopausal hormone therapy and women’s health: An umbrella review. PLoS Medicine, 18(8), e1003731.